An initial loading-dose vitamin D versus placebo after hip fracture surgery: baseline characteristics of a randomized controlled trial (REVITAHIP) by unknown
Mak et al. BMC Geriatrics 2014, 14:101
http://www.biomedcentral.com/1471-2318/14/101RESEARCH ARTICLE Open AccessAn initial loading-dose vitamin D versus placebo
after hip fracture surgery: baseline characteristics
of a randomized controlled trial (REVITAHIP)
Jenson CS Mak1,2*, Linda A Klein3, Terry Finnegan4, Rebecca S Mason5 and Ian D Cameron2Abstract
Background: Hypovitaminosis D is particularly common among older people with a proximal femoral (hip) fracture.
There are currently no agreed strategies for vitamin D replenishment after hip fracture surgery. The REVITAHIP Study
is a multisite, double-blinded randomized-controlled trial investigating the effects of an oral vitamin D loading
dose on gait velocity after hip fracture surgery. We describe the baseline characteristics of participants, aiming to
document hypovitaminosis D and its associations after hip fracture.
Methods: Participants, over 65, recruited within 7 days following hip fracture surgery from 3 Australia hospitals,
were randomly allocated to receive a loading dose of vitamin D3 (250,000IU) or placebo, followed by oral
maintenance vitamin D3/calcium (800 IU/500 mg) and the usual hip fracture rehabilitation pathway. Demographic
and clinical data were collected, including surgical procedure, pre-fracture functional status, Mini Mental State
Examination (MMSE) score, serum 25-hydroxyvitamin D (25-OHD), Verbal Rating Scale (VRS) for pain, grip strength
and gait velocity. The associations of baseline 25-OHD levels with demographic and clinical data were assessed
using Pearson’s correlation, ANOVA and regression analyses.
Results: Two-hundred-and-eighteen people with hip fracture participated in the study. Mean age was 83.9+/-7.2
years, 77% were women and 82% lived in private homes. Fifty-six percent had a subcapital fracture. Mean comorbidity
count was 3.13+/-2.0. Mean MMSE was 26.1+/-3.9. Forty-seven percent of participants had hypovitaminosis D
(<50 nmol/L). Multivariate regression models demonstrated higher baseline vitamin D levels were significantly
associated with higher premorbid Barthel index scores, lower post-operative VRS pain levels and use of vitamin D.
Conclusion: This study cohort shared similar demographic characteristics and comorbidities with other cohorts of
people with hip fracture, with the probable exception of less cognitive impairment. Hypovitaminosis D was not as
prevalent as previously documented. Patients taking vitamin D supplements and with higher premorbid Barthel index,
reflecting greater independence and activity, tended to have higher 25-OHD levels at baseline. Further, lower VRS pain
ratings following surgery were associated with higher vitamin D levels. Such associations will need further investigation
to determine causation. (ANZCTR number, ACTRN12610000392066).
Trial registration: The protocol for this study is registered with the Australian New Zealand Clinical Trials Registry
ANZCTRN ACTRN12610000392066.
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Hip fractures account for the majority of fracture-related
health care expenditure and contribute to substantial
mortality in men and women over the age of 60 years
[1]. By 2040, an estimated 512, 000 hip fractures will
occur in the United States each year at a cost of $16 bil-
lion per year [2], and by 2050, an estimated 76.7 billion
Euros will be spent on this problem in Europe [3]. One
year after fracture, 37.1% of men and 26.4% of women
will have died, compared with an expected annual mor-
tality of about 10% in this age group [4]. More than 10%
of survivors will be unable to return to their previous
residence. Most of the remainder will have some residual
pain or disability [5]. As most people do not recover
fully from a hip fracture, personal and societal costs are
substantial. Following hip fracture, in addition to surgery,
there is often the need for rehabilitation, outpatient visits
for follow-up treatment, and assistance with activities of
daily living at home during the recovery period. Improving
functional parameters following a hip fracture has the po-
tential to be of great benefit to older people by reducing
disability and enhancing quality of life and could also re-
duce direct treatment costs and costs of long-term com-
munity or residential aged care services. Mobility is the
key activity underlying functioning and quality of life [6].
Hypovitaminosis D is commonly associated with hip
fracture in older people. It occurs because of multiple fac-
tors such as decreased sun exposure with reduced skin
production of vitamin D and low dietary D2/D3 intake.
Vitamin D replacement has been used successfully to re-
duce such fractures, as well as falls among older people
[7-9]. However, in the absence of preventive treatment,
hypovitaminosis D following hip fracture may result in
proximal muscle weakness, pain, reduced dynamic balance
and performance speed [10], affecting mobilization during
the acute postoperative and rehabilitation periods [11-15].
The REVITAHIP study (ACTRN12610000392066) is a
multisite, randomized controlled trial examining the effect
of an initial loading dose of vitamin D3 (250,000 IU) on re-
habilitation outcomes following hip fracture surgery [16]. In
this paper, we describe the baseline characteristics of partici-
pants enrolled in this study. The main objective is to com-
pare the REVITAHIP cohort to other cohorts of studies in
which vitamin D has been used proactively to improve out-
comes following hip fracture surgery, as well as with the
Australian population survey of hip fractures from the Aus-
tralian Institute of Health and Welfare (AIWH) [6], with a
focus on hypovitaminosis D, cognitive and functional status.
Methods
Design
This paper presents a cross sectional analysis of the
baseline data from the RCT trial. The RCT methodology
is described in more detail in the protocol paper [16].The Northern Sydney Central Coast Area Health Service
(NSCCAHS) Harbour Human Research Ethics Committee
(HREC) approved the study protocol (HREC Number 10/
HARBR/14) on May 13, 2010.
Participants
Older people admitted to participating public hospital wards
in Sydney, Australia, were invited to participate if they were
aged 65 years or over, presenting with a hip fracture requir-
ing surgical treatment and able to provide informed consent,
either directly or via the “person responsible.” Other inclu-
sion and exclusion criteria are described in the protocol
paper [16]. The Northern Sydney Central Coast Area Health
Service Harbour Human Research Ethics Committee
(HREC) approved the study protocol (HREC Number 10/
HARBR/14) on May 13, 2010.
Randomization
After consent and completion of the baseline assessment,
participants will be formally entered into the study and ran-
domised to intervention or control groups. Randomization
will occur using a computer-generated random number
schedule with variable block sizes of 2 to 6. It will be per-
formed centrally by an investigator not involved in recruit-
ment or assessments. To conceal allocation, study staff will
ring a central telephone number to be notified to which
group the participant has been randomized.
Intervention
Patients in the treatment group received a loading dose
of oral vitamin D3 (5 tablets of 50 000 IU, Calciforte
Strong [API Pharmaceuticals, New Zealand], total 250
000 IU), ideally within 96 hours but up to 7 days post-
surgery. Patients in the control group received 5 placebo
tablets identical in appearance to the active tablets,
ideally within 96 hours but up to 7 days postsurgery.
Both groups were provided with a twice daily oral cal-
cium–vitamin D combination tablet (calcium 500 mg
and vitamin D3 400 IU; Calcia, Nycomed Pharmaceuti-
cals: 2 Lyonpark Road, North Ryde NSW 2113). Partici-
pants unable to tolerate the oral tablet formulations will
be switched to a daily oral sachet of calcium–vitamin D
combination effervescent granules (calcium 1000 mg and
vitamin D3 880 IU; Calvid, Pharmaceutical Special Prod-
ucts: 2 Albert Road, Moonah, Tasmania. Australia 7009).
Those patients in either group with severe hypovitamino-
sis D (25OHD <10 nmol/L) were commenced on an oral
moderate-dose vitamin D of 2000 units twice a day for
14 days to ensure adequate and timely replacement.
Baseline outcome measures
Participants were reviewed at recruitment for descriptive
information including demographic data (age, sex, place of
residence), clinical data (surgical procedure, pre-fracture
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hydroxyvitamin D (25-OHD) using DiaSorin immuno-
assay with cross-reference to Standard Reference Materials
[17,18], serum corrected calcium levels, activities of daily
living (ADLs)/functional status using the Modified Barthel
Index) [19], quality of life (EQ5D) [20], Mini Mental State
Examination (MMSE) [21] and Clock-Drawing Tests [22],
grip strength (using the participant’s dominant hand on a
JAMAR hand dynamometer with maximum reading on 2
attempts [23]) and gait velocity. Weight was measured on
body weight scales, whilst height measurements were
taken using a ‘drop down’ tape measure fixed at about 2
metres on a wall (and from a tape measure in the supine
position when weight-bearing was not possible). Data were
collected for the Functional Comorbidity Index [24] using
direct medical file review, and whenever necessary, add-
itional information was sought from participant’s medical
records.
The study protocol required that a 25-OHD assay be
performed prior to the loading dose. In some cases how-
ever, the 25-OHD level had been requested on the same
day of the loading dose, but was ultimately taken within
24-48 hours after the loading dose. This occurred for 62
(28.4%) of participants. These 62 participants were ex-
cluded from analyses using baseline 25-OHD.
Statistical analysis
Where appropriate, differences between variables of
interest were assessed for statistical significance using
the Pearson chi-square test for categorical variables and
analysis of variance (ANOVA) for continuous variables.
Regression analyses were used to examine the degree of
association between baseline vitamin D levels and demo-
graphic characteristics, fracture type, surgical procedure,
and cognitive status - first at the univariate level, followed
by multivariate modelling to determine those variables
maintaining significance while controlling for all others. A
p value less than .05 was considered statistically signifi-
cant. Data were analyzed using IBM SPSS Version 21.0.
Results
A total of 835 suitable patients were identified over the
study period (January 2011 to April 2013), of whom 218
consented, were randomized and completed assessments
(Figure 1). The participants ranged in age from 65 to
101 years (mean of 83.9+/-7.2 years). A majority (168,
77.1%) were female. Females had a higher mean age than
males (84.6 vs 81.6, p < =0.009). Most participants
(81.7%) were born in Australia and 93.6% spoke English
as the first language. Mean height was 163.0+/-8.7 cm,
mean weight was 66.0+/-11.8 kg, and mean BMI was
24.7+/-3.6 m/kg2. Approximately 83% of participants
had a pre-injury residence in the community, with 44%
of the whole sample living alone. Fourteen percent ofparticipants lived in a residential aged care facility in-
cluding 4% living in a nursing home. Table 1 summarises
the baseline characteristics of the participants.
Participants had a mean Functional Comorbidity Index
of 3.1+/-2.0, ranging from 0 to 9 separate conditions.
The most prevalent comorbid conditions were arthritis
and osteoporosis as shown in Figure 2, which provides
further details of other comorbid conditions.
The number of medications used prior to hip fracture
ranged from 0 to 10 (mean of 4.9+/-2.6). Seventeen per-
cent of participants were either using calcium, vitamin D
or both prior to their hip fracture, while 20% were using
osteoporosis medications other than calcium or vitamin
D, of which 81% were bisphosphonates. Prior to hip frac-
ture 73 (33.5%) participants were using psychotropic
medications with 31.5% of these 73 using two or three,
including antidepressants (49, 67.1%), anxiolytics/seda-
tives (16, 21.9%), opioids (15, 20.5%), anticonvulsants
(8, 11.0%), and antipsychotics (7, 9.6%).
Mean Modified Barthel Index was 87.1+/-21.0 (range
2-100; median = 100) before hip fracture. This means
that, on average, most participants had little or no re-
strictions in mobility and personal activities of daily living.
Specifically, 67.7% of participants reported full independ-
ence in their personal hygiene, specifically bathing self
(65.4%), feeding self (76.0%), toileting (70.0%), stair climb-
ing (60.4%), dressing (68.7%), bowel control (68.7%), blad-
der control (62.2%), ambulation (70.0%) and chair to bed
transfer (75.1%).
Most (94.5%) participants completed the MMSE (7 were
unable and 5 declined). Mean MMSE score was 26.0 +/-
4.3, ranging from 0 to 30, with 16.0% scoring less than or
equal to 23 out of 30. In detail, participants were able to
correctly answer the following MMSE items: orientation
to time (67.8%); orientation to place (76.4%), 3-item regis-
ter (93.8%), attention (51.4%), 3-item recall (37.0%), nam-
ing (82.7%), repeating ‘no ifs ands or buts’ (87.5%), 3-step
command (72.1%), read and obey (97.1%), write sentence
(89.3%), copy a design (77.2%). Half (50.5%) scored 3 out
of 3 in the Clock Drawing Test.
Hip fracture subtype
In all, 107 (50.5%) patients had a subcapital fracture
(9 undisplaced, 98 displaced), while 105 (49.5%) had a
trochanteric fracture (10 simple trochanteric, 75 com-
plex pertrochanteric, 20 subtrochanteric). Fracture de-
tails for six patients are not known.
Surgical details and post-operative weight-bearing status
Mean time from fracture to surgery was 41.3+/-32.4 hours
(median 36.0) and mean length of surgery was 1.8
+/-0.7 hours. Surgical fixation procedures were as fol-
lows: gamma nail (29.1%), dynamic/sliding hip screw
with long plate (18.3%), total hip replacement (18.3%),
Figure 1 REVITAHIP CONSORT 2014 flow diagram.
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mented hemiarthroplasty (eg Austin-Moore) (13.6%),
cemented hemiarthroplasty (8.0%) and cannulated screw(s)
(2.3%). Details for five patients are not known. At a mean
of 3.3 +/- 2.0 days after hip fracture surgery, 73.7% of par-
ticipants were mobilising with unrestricted weight bearing.
Function and pain at time of baseline assessment
Following hip fracture, participants had a significantly re-
duced mean EQ5D Health rating (reflective of function at
the time of assessment) with the majority reporting min-
imal to substantial problems in all functional domains:
pain (78.7%), anxiety/depression (26.9%), mobility (96.3%),
self-care (94.0%) and usual activity (96.8%). The mean
EQ5D health rating was 60.7+/-16.5 (median = 60), ran-
ging from 5 to 100 out of 100. This indicates considerable
restriction which is as expected a short time after hip frac-
ture. The mean grip strength was 16.1+/-6.8 kgs at this
time, while mean VRS pain was 3.5+/-2.3 (median = 3.0)out of 10. More than half (62.5%) had VRS > =3 and 18.5%
had VRS > =5.
Vitamin D levels
For patients in which 25-OHD levels were assessed prior to
the intervention loading dose (n = 156), mean 25-OHD was
52.7+/-23.5 mmol/L (median = 54.0), ranging from 9 to
130 mmol/L. Hypovitaminosis D (<50 nmol/L) was present
in 46.8% of these participants. Vitamin D levels classified by
groups were noted as follows: 15.4% (<30 nmol/L), 31.4%
(30-50 nmol/L), 39.1% (51-75 nmol/L), and 14.1%
(>75 nmol/L). Unsurprisingly, participants who had 25-
OHD levels assessed after the loading dose was given,
showed significantly higher levels than those that were
assessed before the loading dose (70.1 vs 52.7 nmol/L, F =
18.4, p < .001), supporting the need for exclusion from the
following analyses.
In univariate analyses, variables that were significantly
related to pre-loading dose 25-OHD levels were the use
Table 1 Baseline characteristics of participantsa
Continuous variables Mean +/- SD
Age in years 83.9+/-7.2
Categorical variables Percentage
Gender (% women) 77.2%




Body mass indexd in kg/m2 24.6+/-3.6
Pre-injury living statusc



















Hip fracture subtypee - Undisplaced subcapital: 4.3%












- Total hip replacement: 18.5%
- Dynamic hip screw with
short plate: 10.4%
- Dynamic hip screw with
long plate: 18.5%
- Gamma nail: 28.4%
MMSE score (c) 26.0+/-4.35
Using calcium (e) 10.4%












25-hydroxyvitamin D level (f) 52.7+/-23.5 nmol/L
Serum corrected calcium (e) 2.31+/-0.13 mmol/L
Grip strength (e) 16.1+/-6.8 kgs
aAll data are expressed in numbers (% of total) except for
continuous variables.
bExcept calcium and vitamin D.
cMissing data = 4 (n=216).
dMissing data = 28 (n=192).
eMissing data = 10 (n=210).
fMissing data = 65 (n=155).
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supplements (p = 0.027), total number of medications
used (p = 0.048), total Barthel score as a dichotomous
variable (<70/> = 70; p = 0.028) and VRS pain rating
(p = 0.028) as shown in Table 2. That is, use of supple-
ments, greater number of medications, higher Barthel
score and lower VRS pain ratings were associated with
increasing 25-OHD levels. These variables along with
those where p < 0.20 (i.e. total Barthel score as adults
continuous variable, living alone versus with others, and
post-operative weight bearing) and with season when
25-OHD measure was taken (which is thought to influ-
ence 25-OHD levels though not found to be significant
on its own) were examined using multivariate regression
modeling. All other demographic and study variables (i.e.
age, gender, country of birth, use of psychotropic or other
types of medication, total functional comorbidity index,
BMI, obesity, EQ5D measures, MMSE total score, fracture
type, surgical method, serum calcium levels and grip
strength) did not show significant association with 25-
OHD levels and were not included in multivariate model-
ing. The use of Vitamin D supplements, higher total
Barthel Index and lower VRS pain maintained significant
relationship to increasing 25-OHD levels as shown in the
final multivariate model (see Table 3).
Discussion
This study has demonstrated that patients with hip
fracture are likely to have hypovitaminosis D (46.8%)
but a subset was vitamin D replete. The REVITAHIP
results for 25-OHD levels were slightly higher than
those reported by Ish-Shalom et al [12] but similar to
those reported by Papaioannou [13], which ranged
from 44.3 to 58.7 nmol/L.
Furthermore, our multivariate model shows that pre-
morbid Barthel index, post-operative VRS pain and
prior use of vitamin D together were associated with
baseline 25O HD concentrations. This model suggests
that patients with lower Barthel index scores and higher
reported VRS pain were more likely to have lower 25O
Figure 2 Comorbidity types, percentages (n=217).
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were premorbidly less active with correspondingly lower
functional status and those who reported higher pain
scores postoperatively were more likely to show hypovi-
tamosis D following their hip fracture operation. Use of
Vitamin D preparations prior to fracture had a very
clear relationship with higher Vitamin D levels at
baseline.
Similar to previous data [5], this study found that hip
fracture has significant impact on mobility, personal
ADLs and quality of life in the immediate post-acute
period. Participants had a significantly reduced mean
EQ5D Health rating, with the majority reporting min-
imal to substantial problems in all functional domains:
pain, anxiety/depression, mobility, self-care and usual
activity. With regards to comorbidities, we found that
hip fractures occurred in older females with multipleTable 2 Univariate association between dependent variable 2
surgery (n=155), and baseline characteristics
Continuous independent variablea n
Number of medications used 156
VRS pain rating 155
Categorical independent variableb




Using vitamin D 156
No
Yes
aContinuous independent variables were compared individually with 25O HD (cont
bCategorical independent variables were compared individually with 25O HD using
*Indicates statistical significance (p<.05).comorbidities, particularly arthritis, osteoporosis and
visual impairment, which are significantly associated
with falls leading to fractures in the elderly. One-sixth
of REVITAHIP participants scored below the norm in
the MMSE scores, were not in delirium (suggested by
the majority being able to complete a 3-step command
and were oriented), which suggest the cohort had pre-
existing cognitive impairment. However, only 6.9% were
documented to have ‘neurological disease’, suggesting
that the FCI may have underestimated the prevalence of
dementia in our cohort.
A smaller number of REVITAHIP participants (28.9%)
were using calcium, vitamin D and/or other osteopor-
osis medications (e.g. bisphosphonates), despite a much
larger number (45%) with previously documented
osteoporosis on history, suggesting non-adherence as a














inuous dependent variable) using Pearson Correlation Coefficient.
ANOVA.
Table 3 Multivariate regression model: variables associated with baseline 25-hydroxyvitamin D (25-OHD) levels
(n= 150) following backward stepwise method
Variable name B Std. error t p 95% confidence interval
(Constant) 38.553 7.313 5.272 0.000 24.100– 53.006
Using vitamin D (no/yes) 25.633 6.139 4.176 0.000 13.502 – 37.765
Total Barthel -premorbid function(0-100) 0.203 0.079 2.579 0.011 0.048 – 0.359
VRS Pain rating after surgery (0-10) -1.707 0.739 -2.310 0.022 -3.166 – -0.247
r2 = 0.157; model significant at p<0.001.
Variables excluded on 5 previous steps: Using calcium (no/yes), post-operative weight bearing (weight-bearing(WB)/Non-WB+Partial-WB), season of Vit D measurement
(winter/other season), pre-admission residence (alone/with others), total number of medications (0-10).
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Furthermore, a third of participants were on psycho-
tropic medications including antipsychotics, opioids,
antidepressants, anxiolytics, sedatives and/or anticon-
vulsants, reflecting the strong role of psychotropic
medications as a risk factor for falls leading to hip
fracture.
We note that compared to the NICE guidelines [25]
which recommended ‘hip fracture surgery (be per-
formed) on the day of, or the day after, admission’
(0-24 hours), our cohort had a longer median time to
surgery (36 hours). Most of these delays were attrib-
uted to ‘due processes’ and it is possible that, the
delay in hip fracture surgery may contribute to a
delay in the ‘early mobilisation’ step in patients’
rehabilitation.
The strengths of this study are the inclusion of people
with hip fracture who have similar characteristics to the
Australian report of 16,518 patients with hip fracture [8]
with a similar mean age (83.0 vs 83.9 years), hip fracture
subtype (53% vs 51% with neck femur fractures), and
mode of surgery (61.3% vs 60.1% internal fixation). The
weaknesses of this study are in the under-recruitment of
people with severe pre-existing disability compared to
the usual population with hip fractures: (1) low number
of participants from residential aged care facility; (2)
participants with fewer total comorbidities; (3) a small
number with preexisting cognitive impairment (16.0%),
although one-sixth was actually documented in cognitive
impairment in our cohort, suggesting either underre-
porting of the disease at recruitment, or first diagnosis
of disease following a hip fracture. Our cohort of partici-
pants had relatively good function with moderate inde-
pendence prior to their hip fracture, likely due to the
inclusion and exclusion criteria. However, the investiga-
tors believe that this could also be considered a strength,
as it alerts clinicians to potential problems (e.g. in ADLs,
mobility, high psychotropic medication use) even in a
relatively good functioning cohort. Finally, our partici-
pants had a higher level of 25O HD compared to ex-
pected, likely owing to a less frail participant population.Conclusions
This study cohort shared similar demographic character-
istics and comorbidities with other cohorts of people
with hip fracture, with the probable exception of less
cognitive impairment. Hypovitaminosis D was not as
prevalent as documented in some other studies. Patients
taking vitamin D supplements and with higher premor-
bid Barthel index, reflecting greater independence and
activity, tended to have higher 25-OHD levels at base-
line. Further, lower VRS pain ratings following surgery
were associated with higher vitamin D levels, but this is
also consistent with greater independence and activity.
Such associations will need further investigation to de-
termine causation.
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